You are here

A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression

Last updated on October 4, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Cairns, Queensland, 4870 Australia
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Major Depressive Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Primary diagnosis of DSM-IV Major Depressive Disorder, single episode or recurrent,
without psychotic features. Additional DSM-IV Axis I diagnoses will be permitted only
if they are identified as secondary diagnoses.

- Hamilton-Depression rating scale (HAM-D; 17 item) total score ≥18 and HAMD item 1
(depressed mood) score ≥2.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Use of an antidepressant within 2 weeks of baseline (4 weeks for fluoxetine)

- Current or past diagnosis of bipolar disorder or any psychotic disorder.

NCT00644982
Pfizer
Completed
A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders, Pain Crisis, Vaso-occlusive Crisis
NCT02433158
All Genders
6+
Years
Multiple Sites
Major Depressive Disorder
NCT02548949
All Genders
19+
Years
Multiple Sites
Major Depressive Disorder
NCT00474708
All Genders
18+
Years
Multiple Sites
Anxiety Disorders, Depression
NCT00546923
All Genders
A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression
A Multicenter Randomized, Double-Blind, Parallel-Group Study of Sertraline Versus Venlafaxine XR in the Acute Treatment of Outpatients With Major Depressive Disorder
To assess the comparative efficacy of sertraline versus venlafaxine XR on measures of quality of life.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Depressive Disorder, Major
  • Drug: sertraline
    Flexibly-titrated 50 mg tablets, 50-150 mg/day and venlafaxine placebo orally for 10 weeks.
    Other Name: Zoloft
  • Drug: venlafaxine XR
    Flexibly-titrated 75 mg capsules, 75-225mg/day and sertraline placebo orally for 10 weeks.
  • Experimental: Sertaline group
    Intervention: Drug: sertraline
  • Active Comparator: Venlafaxine group
    Intervention: Drug: venlafaxine XR
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
163
September 2003
Not Provided

Inclusion Criteria:

  • Primary diagnosis of DSM-IV Major Depressive Disorder, single episode or recurrent, without psychotic features. Additional DSM-IV Axis I diagnoses will be permitted only if they are identified as secondary diagnoses.
  • Hamilton-Depression rating scale (HAM-D; 17 item) total score ?18 and HAMD item 1 (depressed mood) score ?2.

Exclusion Criteria:

  • Use of an antidepressant within 2 weeks of baseline (4 weeks for fluoxetine)
  • Current or past diagnosis of bipolar disorder or any psychotic disorder.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Turkey
 
 
NCT00644982
A0501066
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2008

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now